Siponimod
Brand names: Mayzent · Active ingredient: Siponimod
In short: MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
What is Siponimod used for?
MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Siponimod dosage
Before initiation of treatment with MAYZENT, assess the following:
CYP2C9 Genotype Determination
Test patients for CYP2C9 variants to determine CYP2C9 genotype [see Dosage and Administration (2.2, 2.3), Contraindications (4) and Use in Specific Populations (8.6)]. An FDA-cleared or -approved test for the detection of CYP2C9 variants to direct the use of siponimod is not currently available.
Cardiac Evaluation
Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present. In patients with certain preexisting conditions, advice from a cardiologist and first-dose monitoring is recommended .
Determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction .
Complete Blood Count
Review results of a recent complete blood count (CBC) .
Liver Function Tests
Obtain recent (i.e., within last 6 months) transaminase and bilirubin levels .
Ophthalmic Evaluation
Obtain a baseline evaluation of the fundus, including the macula, near the start of the treatment with MAYZENT .
Skin Examination
Obtain a baseline skin examination prior to or shortly after initiation of MAYZENT. If a suspicious skin lesion is observed, it should be promptly evaluated .
Current or Prior Medications
If patients are taking anti-neoplastic, immunosuppressive, or immune-modulating therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with MAYZENT .
Vaccinations
Test patients for antibodies to varicella zoster virus (VZV) before initiating MAYZENT; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with MAYZENT .
Maintenance Dosage
After treatment titration , the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6. Dosage adjustment is required in patients with a CYP2C9*1/*3 or *2/*3 genotype .
Administer tablets whole; do not split, crush, or chew MAYZENT tablets.
Treatment Initiation
Initiate MAYZENT with a 5-day titration, as shown in Table 1 . A 12-tablet starter pack should be used for patients who will be titrated to the 2-mg maintenance dosage .
Titration | Titration dose | Titration regimen
Day 1 | 0.25 mg | 1 x 0.25 mg
Day 2 | 0.25 mg | 1 x 0.25 mg
Day 3 | 0.50 mg | 2 x 0.25 mg
Day 4 | 0.75 mg | 3 x 0.25 mg
Day 5 | 1.25 mg | 5 x 0.25 mg
If one titration dose is missed for more than 24 hours, treatment needs to be reinitiated with Day 1 of the titration regimen.
Maintenance Dosage
In patients with a CYP2C9*1/*3 or *2/*3 genotype, after treatment titration , the recommended maintenance dosage of MAYZENT is 1 mg taken orally once daily starting on Day 5.
Administer tablets whole; do not split, crush, or chew MAYZENT tablets. …
How to take Siponimod — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Administration
Tell patients not to discontinue MAYZENT without first discussing this with the prescribing physician. Advise patients to contact their physician if they accidentally take more MAYZENT than prescribed.
Instruct patients to administer tablets whole; do not split, crush, or chew MAYZENT tablets.
Risk of Infections
Inform patients that they may have an increased risk of infections, some of which could be life-threatening, when taking MAYZENT, and that they should contact their physician if they develop symptoms of infection . Advise patients that the use of some vaccines containing live virus (live-attenuated vaccines) should be avoided during treatment with MAYZENT and MAYZENT should be paused 1 week prior and until 4 weeks after a planned vaccination. Recommend that patients postpone treatment with MAYZENT for at least 1 month after VZV vaccination. Inform patients that prior or concomitant use of drugs that suppress the immune system may increase the risk of infection. …
Warnings & precautions
Do not take this medicine if: MAYZENT is contraindicated in patients who have:
A CYP2C9*3/*3 genotype
In the last 6 months experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure
Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has a functioning pacemaker
Known hypersensitivity to siponimod, or to any of the inactive ingredients in MAYZENT. Observed reactions include angioedema .
Risk of Infections
MAYZENT causes a dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values because of reversible sequestration of lymphocytes in lymphoid tissues. MAYZENT may therefore increase the risk of infections, some serious in nature . Life-threatening and rare fatal infections have occurred in association with MAYZENT.
In Study 1 , the overall rate of infections was comparable between the MAYZENT-treated patients and those on placebo (49.0% vs. 49.1%, respectively). However, herpes zoster, herpes infection, bronchitis, sinusitis, upper respiratory infection, and fungal skin infection were more common in MAYZENT-treated patients. In Study 1, serious infections occurred at a rate of 2.9% in MAYZENT-treated patients compared to 2.5% of patients receiving placebo.
Before initiating treatment with MAYZENT, results from a recent CBC (i.e., within 6 months or after discontinuation of prior therapy) should be reviewed.
Initiation of treatment with MAYZENT should be delayed in patients with severe active infection until resolution. Because residual pharmacodynamic effects, such as lowering effects on peripheral lymphocyte count, may persist for up to 3 to 4 weeks after discontinuation of MAYZENT, vigilance for infection should be continued throughout this period . …
Siponimod side effects
The following serious adverse reactions are described elsewhere in the labeling:
Infections
Progressive Multifocal Leukoencephalopathy
Macular Edema
Bradyarrhythmia and Atrioventricular Conduction Delays
Respiratory Effects
Liver Injury
Cutaneous Malignancies
Hypersensitivity
Increased Blood Pressure
Fetal Risk
Posterior Reversible Encephalopathy Syndrome
Unintended Additive Immunosuppressive Effects From Prior Treatment With Immunosuppressive or Immune-Modulating Therapies
Severe Increase in Disability After Stopping MAYZENT
Immune System Effects After Stopping MAYZENT
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 1737 MS patients have received MAYZENT at doses of at least 2 mg daily. These patients were included in Study 1 and in a Phase 2 placebo-controlled study in patients with MS. In Study 1, 67% of MAYZENT-treated patients completed the double-blind part of the study, compared to 59.0% of patients receiving placebo. Adverse events led to discontinuation of treatment in 8.5% of MAYZENT-treated patients, compared to 5.1% of patients receiving placebo. The most common adverse reactions (incidence at least 10%) in MAYZENT-treated patients in Study 1 were headache, hypertension, and transaminase increases. …
Drug interactions
MAYZENT has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration .
When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects .
Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with MAYZENT after alemtuzumab is not recommended.
MAYZENT can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.
MAYZENT has not been studied in patients taking QT prolonging drugs.
Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. If treatment with MAYZENT is considered, advice from a cardiologist should be sought. …
About this medicine
MAYZENT tablets contains siponimod, an S1P receptor modulator, as 2:1 co-crystal of siponimod and fumaric acid and has the following chemical name:
1-[[4-[(1E)-1-[[[4-Cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]imino]ethyl]-2-ethylphenyl]methyl]-3-azetidinecarboxylic acid (2E)-2-butenedioate (2:1). Its molecular formula is C4H4O4•2C29H35F3N2O3, and its molecular weight is 1149.29 g/mol.
Its structure is shown below:
It is a white to almost white powder.
MAYZENT is provided as 0.25 mg, 1 mg, and 2 mg film-coated tablets for oral use. Each tablet contains 0.25 mg, 1 mg, or 2 mg siponimod, equivalent to 0.28 mg, 1.11 mg, or 2.22 mg as 2:1 co-crystal of siponimod and fumaric acid, respectively. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 44492772-5aed-4627-bd85-e8e89f308bb3. Read the full official label on DailyMed.